PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
तुलना करने के लिए मीट्रिक्स | PHXM | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधPHXMपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −0.7x | −3.6x | −0.6x | |
PEG अनुपात | - | −0.06 | 0.00 | |
क़ीमत/बुक | 0.6x | 0.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 7.6x | 6.0x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 159.9% | 172.7% | 47.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 2.6% | 6.7% | अनलॉक करें |